Partnering With Established Viral Vector Manufacturing Platforms to Accelerate PPQ Readiness & Reduce Commercialization Risk
11:45 am - Wednesday 24th February 2027
- Partnering with experienced viral vector CDMOs to accelerate commercialization readiness through proven manufacturing expertise and regulatory support
- Leveraging established platform knowledge to streamline process characterization activities and reduce validation timelines, costs, and resource burden
- Utilizing manufacturing experience and historical data to strengthen regulatory responses and demonstrate consistent PPQ performance
